EyePoint's drug for age-related eye disease fails late-stage trial, shares tank

EyePoint's experimental drug Duravyu failed to meet the primary endpoint in a late-stage trial for wet age-related macular degeneration, with some patients experiencing vision loss unrelated to the disease, resulting in a significant share price drop. The company plans a U.S. FDA filing in 2027 pending second trial results, but regulatory approval remains challenging without two successful trials.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.